AstraZeneca PLC

Most Recent

  • AstraZeneca vaccine syringes
    Healthcare

    Is the AstraZeneca Vaccine Approved in the U.S.?

    By Kathryn Underwood
  • best vaccine stock to buy
    Healthcare

    Best COVID-19 Vaccine Stocks to Buy Now for 2021

    By Ambrish Shah
  • is astrazeneca an american company
    Company & Industry Overviews

    U.K. Government Approves AstraZeneca's Coronavirus Vaccine

    By Kori Williams
  • astrazen main
    Healthcare

    How to Get Help With Your Prescriptions With AstraZeneca Patient Assistance

    By Rachel Curry
  • Alexion Acquisition AstraZeneca
    Healthcare

    AstraZeneca to Acquire Alexion for $39 Billion, Stock Down

    By Ambrish Shah
  • is astrazeneca a buy
    Financials

    Is AstraZeneca Stock Right for Your Portfolio After Alexion Announcement?

    By Ruchi Gupta
  • what drugs does astrazeneca make
    Healthcare

    What Drugs Does AstraZeneca Make?

    By Kathryn Underwood
  • uploads///Article
    Company & Industry Overviews

    How Did AstraZeneca’s CVMD Franchise Perform in 2014?

    In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Illumina Exploring In Vitro Fertilization Opportunities

    Illumina is working in the reproductive health market to enhance the efficacy of in vitro fertilization tools.

    By Margaret Patrick
  • uploads///Article
    Company & Industry Overviews

    AstraZeneca’s ING Franchise Saw Lower Revenues in 2014

    For 2014, AstraZeneca’s ING franchise generated nearly $8.2 billion, a 8.9% decrease as compared to $9.0 billion in 2013.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Consistent Performance Measurement May Improve Novartis’s R&D

    Novartis (NVS) has been focused on consistently measuring the performance of its research and development (or R&D) programs using metrics such as output, cost, returns, quality, and cycle time.

    By Margaret Patrick
  • uploads///ANR
    Company & Industry Overviews

    Analysts’ Expectations for Sanofi

    According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    AstraZeneca’s Lynparza Gives a Strong Performance in Q1

    In the first quarter, AstraZeneca’s (AZN) Lynparza sales rose 99% YoY (year-over-year) to $237 million on a reported basis, driven by the drug’s rapid uptake in first-line ovarian cancer maintenance and metastatic breast cancer.

    By Margaret Patrick
  • uploads///chart
    Macroeconomic Analysis

    Shire Led EWU as the Healthcare Sector Rallied on December 2

    On December 2, stocks at the top of the iShares MSCI United Kingdom Index were Merlin Entertainment (MERL-LON), Shire (SHP-LON) (SHPG-LON), and GlaxoSmithKline.

    By Renee Blakely
  • uploads///chart_
    Company & Industry Overviews

    Recent Developments for Ionis Pharmaceuticals

    On March 6, 2017, Ionis and Akcea announced positive results from the Phase III study APPROACH, evaluating volanesorsen for the treatment of patients with FCS.

    By Mike Benson
  • uploads///INTC
    Fund Managers

    AQR Capital increases stake in Intel

    Intel generated ~$5.7 billion in cash from operations. The company paid quarterly dividends of $1.1 billion and repurchased 122 million shares for $4.2 billion.

    By Diana Key
  • uploads///geon
    Real Estate

    Why AQR Capital exits its position in Geo Group Inc.

    AQR Capital sold a position in GEO Group Inc. in 2Q14. The company accounted for a 0.0206% position in the fund’s first quarter U.S. long portfolio.

    By Patricia Garner
  • uploads///UK
    Macroeconomic Analysis

    Manufacturing Production Remains Negative in the UK

    With the decline in manufacturing output, the iShares MSCI United Kingdom ETF (EWU) has fallen 6.6% over the past month as of January 12.

    By Lara Sheldon
  • uploads///Chart
    Earnings Report

    Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16

    AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

    By Mike Benson
  • uploads///valuation
    Company & Industry Overviews

    Listing the Reasons behind Pfizer’s Discounted Price-to-Earnings

    Considering the robust growth prospects for many of its products going forward, Pfizer should return to robust top line growth.

    By Jillian Dabney
  • uploads///pills _
    Earnings Report

    How AbbVie Fared in Q2 2018

    Driven by growth in Humira, Imbruvica, and Mavyret sales, AbbVie (ABBV) delivered strong Q2 2018 results on July 27.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    What Does AstraZeneca’s Growth Platform Offer?

    The RI&A (respiratory, inflammation and autoimmunity) segment one of the company’s growth platforms, is a key area of development for AstraZeneca (AZN).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts Give Mixed Recommendations for Novartis

    Novartis’s stock price has fallen ~7.0% in the last 12 months and ~10.7% year-to-date.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Analyst Recommendations for AstraZeneca in June 2017

    In 1Q17, AstraZeneca (AZN) reported revenues close to $5.4 billion, which is a fall of around 12.0% on a YoY (year-over-year) basis.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    AstraZeneca’s Other Products in 3Q16

    With lower sales from blockbuster drugs Nexium and Seroquel, the contribution of AstraZeneca’s (AZN) Other segment fell to ~21.2% in 3Q16.

    By Mike Benson
  • astrazeneca
    Healthcare

    AstraZeneca and Other COVID-19 Vaccine Trials Seek Volunteers

    By Rachel Curry
  • uploads///syringe _
    Earnings Report

    AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates

    AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products.

    By Mike Benson
  • uploads///Total IG Bond Issuance for November
    Company & Industry Overviews

    Halliburton Company Led High-Grade Bond Issuance in November

    Halliburton Company (HAL) issued A2/A rated high-grade bonds worth $7.5 billion in November.

    By Lynn Noah
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    Key Risks Facing Sucampo Pharmaceuticals in 2017

    Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

    By Kenneth Smith
  • uploads///Total IG Bond Issuance for the Week Ending November
    Company & Industry Overviews

    AstraZeneca Issued High-Grade Bonds to Acquire ZS Pharma

    Last week, AstraZeneca issued A2/A rated high-grade bonds worth $6.0 billion to fund the acquisition of ZS Pharma (ZSPH).

    By Lynn Noah
  • uploads///Novavax RSV Pipeline
    Company & Industry Overviews

    Exploring Novavax’s Vaccine Candidates for RSV

    According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

    By Kenneth Smith
  • uploads///PFE MDVN deal
    Company & Industry Overviews

    What’s the Story behind the Pfizer-Medivation Deal?

    Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s to Be Expected from Novartis’s 3Q16 Earnings?

    Novartis, one of the world’s largest pharmaceutical companies by revenue, is set to release its 3Q16 earnings on October 25, 2016.

    By Mike Benson
  • uploads///Chart  AZN
    Company & Industry Overviews

    How AstraZeneca’s 1Q18 Shook Out

    AstraZeneca stock has fallen ~1.2% in 1Q18, and its stock has risen ~2.1% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Bristol-Myers Squibb’s 2Q16 Estimates: Other Segments

    Bristol-Myers Squibb’s (BMY) neuroscience segment is represented by the drug Abilify, while its immuno-science segment is represented by the drug Orencia.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s New Oncology Portfolio May See Healthy Growth

    In 1Q17, AstraZeneca’s (AZN) new oncology portfolio reported global sales of around $236.0 million. Tagrisso earned revenues of $171.0 million globally.

    By Margaret Patrick
  • uploads///freestocks org  unsplash
    Company & Industry Overviews

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Why Repatha Could Be One of Amgen’s Largest Opportunities for 2016

    Despite Repatha’s slower-than-expected uptake after its launch in 2015, Amgen (AMGN) is confident of the drug’s future commercial prospects.

    By Margaret Patrick
  • uploads///Neuroscience
    Earnings Report

    Bristol-Myers Squibb’s Neuroscience and Immunoscience Segments

    Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Bristol-Myers Squibb’s Other Segments

    Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

    By Mike Benson
  • Healthcare

    Why AstraZeneca’s oncology pipeline is attractive to Pfizer

    Pfizer (PFE) is seeking to expand its oncology franchise and a combination with AstraZeneca (AZN) would be meaningful due to the latter’s pipeline of cancer drugs.

    By Samantha Nielson
  • uploads///Astrazeneca versus Shire
    Macroeconomic Analysis

    Amec Foster Wheeler’s Steep Fall Pushed Down Energy Sector, EWU

    Amec Foster Wheeler (AMFW) declared it will halve its dividends due to the fall in oil prices. Its trailing 5-day and trailing one-month returns were -20.1% and -28.3%, respectively, as of November 5.

    By Renee Blakely
  • uploads///Chart  GSK
    Company & Industry Overviews

    How GlaxoSmithKline Stock Performed in 1Q18

    GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///lung cancer
    Company & Industry Overviews

    Why Is Lung Cancer so Attractive to Bristol, Merck, and Roche?

    Bristol-Myers Squibb’s (BMY) Opdivo’s will now share the second-line lung cancer therapy market with Roche’s Tecentriq, along with Merck’s Keytruda.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Valuation Report Card: How Did It Score?

    The fundamental factors affecting stock prices and valuation include the performance of growth platforms as well as the exclusivity of blockbuster drugs.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca Is Taking Steps to Improve Its Position in Oncology

    During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

    By Mike Benson
  • uploads///gks
    Earnings Report

    How Did Novavax Perform in 2Q15?

    Novavax (NVAX) posted a variety of positive qualitative and quantitative performance indicators in 2Q15.

    By Gabriel Kane
  • uploads///Kisqali BTD
    Company & Industry Overviews

    Novartis Receives 2 Breakthrough Therapy Designations in January

    In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.

    By Daniel Collins
  • uploads///Krystexxa
    Company & Industry Overviews

    Introducing Krystexxa, the Latest Addition to Horizon’s Orphan Portfolio

    In January 2016, Horizon acquired Krystexxa from Crealta Holdings. The drug has been approved by the FDA for the treatment of chronic refractory gout.

    By Jillian Dabney
  • uploads///cancer _
    Company & Industry Overviews

    Tesaro Stock Up over 16% on Rumors of Acquisition by Roche

    Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.

    By Sarah Collins
  • uploads///BYI
    Fund Managers

    AQR Capital initiated position in Bally Technologies Inc.

    AQR Capital initiated a position in Bally Technologies during the third quarter of 2014 that accounts for 0.22% of the fund’s 3Q14 portfolio.

    By Diana Key
  • uploads///Van Eck Video
    Macroeconomic Analysis

    What Are Generic Drugs and Why Are They Important?

    TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]

    By VanEck
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?

    Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017

    On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    How Merck’s Human Vaccines Business Performed in 1Q18

    In 1Q18, Merck’s (MRK) human vaccines business saw its total revenue grow 4.2% YoY (year-over-year) to $1.5 billion from $1.4 billion.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Are Merck’s Key Growth Drivers for 2019?

    Merck & Co. (MRK) highlighted its oncology, vaccines, hospital and specialty care, and animal health businesses as its key growth drivers in 2018.

    By Margaret Patrick
  • uploads///SPY and EWU ETF Movement
    Macroeconomic Analysis

    UK Stock Market Continues its Downward Momentum as EWU Lost 1.75%

    On September 18, the UK stock market experienced a fall in consumer staples. The financial sector also fell steeply.

    By Renee Blakely
  • uploads///Ibrance
    Company & Industry Overviews

    Analyzing Pfizer’s Ibrance and Xalkori after 2Q17

    In the US market in 4Q17, Ibrance generated revenues of $777 million, which reflected ~27% growth on a YoY basis.

    By Daniel Collins
  • uploads///US Investment Grade Bond Fund Flows
    Company & Industry Overviews

    Investment-Grade Bond Funds Saw Outflows in November

    According to Lipper’s funds flow data, investment-grade bond funds saw net outflows of $789.1 million up to the week ending November 25.

    By Lynn Noah
  • uploads///Oncology
    Earnings Report

    AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?

    AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Will Be a Key Driver of Biogen’s Future Valuations?

    Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).

    By Margaret Patrick
  • Real Estate

    Why AQR Capital increased its position in Apple in 2Q14

    AQR Capital increased its position in Apple from 0.86% in the previous quarter to 1.24% in the fund’s second quarter U.S. long portfolio.

    By Patricia Garner
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Key Focus: Oncology

    AstraZeneca’s (AZN) key focus is its oncology segment. The segment’s contribution increased to more than 12% in 1Q16. Its key products include Zoladex, Faslodex, and Iressa.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca May Witness a Fall in 2017 Net Profit Margin

    Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Other Drugs for Non-small Cell Lung Cancer

    Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

    By Mike Benson
  • uploads///inorganic growth
    Company & Industry Overviews

    Four Key Deals: Analyzing Pfizer’s Impending Growth

    Over the past year, Pfizer completed multiple acquisitions to restore its top line growth. They will offset the revenue decline and fuel Pfizer’s top line.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017

    Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    This Could Be a Solid Growth Driver for Myriad Genetics in 2018

    Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Oncology Segment: Another Growth Platform for AstraZeneca?

    The oncology segment is another key focus area of AstraZeneca (AZN). The oncology segment’s contribution increased from ~11.6% in 2014 to ~12.1% in 2015.

    By Mike Benson
  • uploads///salix
    Company & Industry Overviews

    What Might Have Fueled Valeant’s Interest in Salix?

    The gastrointestinal (or GI) drug market in the United States is expected to grow at a CAGR of 5.0% over a five-year period from 2014 to 2019.

    By Jillian Dabney
  • uploads///Recent wins
    Earnings Report

    Brodalumab, Oral Relistor among Valeant’s Recent Wins

    Valeant’s (VRX) recent wins include the FDA’s advisory committee vote in favor of approving brodalumab for the indication of mild to moderate psoriasis.

    By Jillian Dabney
  • uploads///Chart
    Miscellaneous

    Teva’s Respiratory Drugs Contribute 11% to Specialty Medicines

    Teva’s respiratory drugs franchise provides solutions for asthma, COPD, and allergic rhinitis. Respiratory drugs contributed nearly 11% of total revenues for Teva’s Specialty Medicines in 2014.

    By Mike Benson
  • uploads///gks
    Earnings Report

    How Has Aquinox Performed Compared to Peers?

    Aquinox has a positive future outlook and will likely continue to better its performance in the near future.

    By Gabriel Kane
  • uploads///PE
    Company & Industry Overviews

    Does Pfizer Deserve a Better Valuation?

    Like other big pharmaceutical companies, Pfizer witnessed negative top line growth. With multiple acquisitions recently, it’s poised to grow its top line.

    By Jillian Dabney
  • uploads///Chart  NVO
    Miscellaneous

    Performance of Novo Nordisk Stock in 2Q17

    Novo Nordisk (NVO) stock has risen ~18.6% in 2Q17. It has risen ~16.9% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///revenue projections
    Company & Industry Overviews

    How Much Could Gilead Sciences’s Revenues Fall beyond 2016?

    Gilead Sciences (GILD) is expected to garner $28.3 billion in 2017 and $26.7 billion in 2018.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for Novartis on April 17

    Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16.

    By Mike Benson
  • uploads///nutrient additives _
    Company & Industry Overviews

    What Boosted Merck’s Stock Price on April 9

    On April 9, 2018, Merck (MRK) stock rose ~4.4% in early trading and ~2.7% during the day.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb: What Do Its Other Segments Offer?

    Bristol-Myers Squibb’s (BMY) neuroscience segment’s sales declined by 63.0% in 2015 from 2014, while its immunoscience segment’s sales improved ~14.1%.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Recommendations for GlaxoSmithKline in May

    GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.

    By Mike Benson
  • who owns astrazeneca
    Healthcare

    Is AstraZeneca Stock a Good Buy at These Prices?

    By Ambrish Shah
  • Company & Industry Overviews

    Financials: Biggest Negative Contributor to PEUGX in 1Q16

    The Putnam Europe Equity Fund – Class A (PEUGX) fell 4.3% in 1Q16, making it a below-average performer among the 12 funds in this review. In the past one year, PEUGX has fallen 7.9%

    By David Ashworth
  • astrazeneca covid vaccine resumes trials
    Healthcare

    AstraZeneca Resumes COVID-19 Clinical Trials in U.K., Stock Up

    By Ambrish Shah
  • operation warp speed companies
    Healthcare

    Operation Warp Speed Has Invested Billions in Potential COVID-19 Vaccines

    By Ambrish Shah
  • AstraZeneca Halts COVID-19 Vaccine Study After Unexplained Illness
    News

    AstraZeneca Halts COVID-19 Vaccine Study After Unexplained Illness

    By Mark Pygas
  • uploads///patent cliff top
    Company & Industry Overviews

    Why the Patent Cliff Is a Key Driver of Generic Drug Growth

    Over the last several years, patent cliffs have led to steep revenue losses for traditional pharmaceuticals as well as created a gateway for smaller companies to come to market with generics.

    By VanEck
  • AstraZeneca Secures Deal With Australia for COVID-19 Vaccine
    Healthcare

    AstraZeneca Secures Deal With Australia for COVID-19 Vaccine

    By Mark Pygas
  • uploads///Graph
    Miscellaneous

    Which Biotechnology Companies Could Benefit from Brexit?

    The weak pound is expected to negatively affect biotechnology companies with a high revenue exposure to the United Kingdom.

    By Margaret Patrick
  • uploads///Novavax Revenue Growth
    Company & Industry Overviews

    Chart in Focus: Novavax’s Financial Position in 2017

    Novavax (NVAX) generated revenues of $8.4 million in 3Q17 compared with $3.2 million in 3Q16.

    By Kenneth Smith
  • uploads///fixing of dermatology business
    Company & Industry Overviews

    How Valeant Plans to Its Fix Dermatology Portfolio

    Actions to fix dermatology portfolio After the Philidor separation, Valeant Pharmaceuticals’ (VRX) dermatology business has suffered a lot. If you want to learn more about this controversy, please read What Happened in the Valeant-Philidor Controversy? Valeant’s actions to stop the declining dermatology business include a 20-year fulfillment program with Walgreens, a newly launched prior authorization approval […]

    By Jillian Dabney
  • uploads///PD  class action
    Company & Industry Overviews

    Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

    The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.

    By Jillian Dabney
  • uploads///Neurociences
    Company & Industry Overviews

    Johnson & Johnson’s Neuroscience Segment in 2017

    In 4Q17, Risperdal Consta generated revenues of $197.0 million, which is an ~6.2% decline on a YoY basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Analyzing Eli Lilly’s Clinical and Business Developments in 1Q16

    Elanco, the animal healthcare arm of Eli Lilly, received exclusive and global rights to develop and commercialize Aratana’s (PETX) Gallipart, a drug that treats osteoarthritis in dogs.

    By Mike Benson
  • uploads///annual revenue
    Company & Industry Overviews

    How Much Could Pfizer Grow beyond 2016?

    Year-to-date, Pfizer’s (PFE) stock has already fallen 4.2%. Despite its multiple acquisitions to boost its falling top line, investors are cautious about the company.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Will Merck & Co.’s Revenue Recover in 4Q15?

    Analysts’ expect Merck & Co.’s (MRK) revenue for 4Q15 to be ~$10.3 billion. It’s nearly 1.6% lower than $10.5 billion in revenue reported for 4Q14.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How AstraZeneca’s Oncology Products Performed in 4Q17

    AstraZeneca’s (AZN) oncology products include legacy oncology products as well as new oncology products.

    By Mike Benson
  • uploads///AZN
    Company & Industry Overviews

    Major Expected Events from AstraZeneca’s R&D in H2 2018

    AstraZeneca has seen major recent product approvals such as Lynparza in Japan for breast cancer and Tagrisso in the EU for lung cancer.

    By Kenneth Smith
  • uploads///Graph
    Earnings Report

    AstraZeneca’s Expense Guidance for Fiscal 2019

    In its first-quarter press release, AstraZeneca (AZN) guided for its fiscal 2019 core operating expenses rising YoY (year-over-year) by a low single-digit percentage.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.